MedTrace Logo

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

NCT04162353 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-16

No results posted yet for this study

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.

Conditions

  • Multiple Myeloma in Relapse
  • Refractory Multiple Myeloma
  • Plasmacytoid; Lymphoma

Interventions

BIOLOGICAL

BCMA-CD19 cCAR T cells

BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy

Sponsors & Collaborators

  • iCAR Bio Therapeutics Ltd.

    collaborator INDUSTRY

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • iCell Gene Therapeutics

    lead INDUSTRY

Principal Investigators

  • Hongyu Zhang, MD/PhD · Peking University Shenzhen Hospital, China

  • Fang Liu, MD/PhD · Chengdu Military General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162353 on ClinicalTrials.gov